TR200101204T2 - Dialkil Fumaratlarının kullanımı - Google Patents
Dialkil Fumaratlarının kullanımıInfo
- Publication number
- TR200101204T2 TR200101204T2 TR2001/01204T TR200101204T TR200101204T2 TR 200101204 T2 TR200101204 T2 TR 200101204T2 TR 2001/01204 T TR2001/01204 T TR 2001/01204T TR 200101204 T TR200101204 T TR 200101204T TR 200101204 T2 TR200101204 T2 TR 200101204T2
- Authority
- TR
- Turkey
- Prior art keywords
- fumarates
- dialkil
- preparations
- micro
- transplantation medicine
- Prior art date
Links
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 title abstract 4
- 239000003814 drug Substances 0.000 abstract 3
- 238000002360 preparation method Methods 0.000 abstract 2
- 238000002054 transplantation Methods 0.000 abstract 2
- 108010036941 Cyclosporins Proteins 0.000 abstract 1
- 229930182912 cyclosporin Natural products 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 229960003444 immunosuppressant agent Drugs 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000006187 pill Substances 0.000 abstract 1
- 230000002269 spontaneous effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fats And Perfumes (AREA)
Abstract
Bulus,dialkil fumaratlarinin, transplantasyon hekimliginde veya bagisiklik sisteminde kendiliginden olusan hastaliklarin tedavisinde uygulanan tibbi ecza preparatlarinin ve dialkil fumaratlari içeren mikro tablet veya mikro haplar seklindeki tibbi ecza preparatlarinin imalatinda kullanilmasi ile ilgilidir. Dialkil fumaratlari bu amaçla transplantasyon hekimliginde alisilagelmis preparatlarla ve özellikle immünosüpresifler gibi siklosporinlerle kombinasyon halinde de kullanilabilmektedir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19853487A DE19853487A1 (de) | 1998-11-19 | 1998-11-19 | Verwendung von Dialkylfumaraten |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200101204T2 true TR200101204T2 (tr) | 2001-09-21 |
Family
ID=7888396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2001/01204T TR200101204T2 (tr) | 1998-11-19 | 1999-10-29 | Dialkil Fumaratlarının kullanımı |
Country Status (34)
Country | Link |
---|---|
US (9) | US6509376B1 (tr) |
EP (1) | EP1131065B1 (tr) |
JP (7) | JP2002530324A (tr) |
CN (2) | CN1615839A (tr) |
AT (1) | ATE242633T1 (tr) |
BE (1) | BE2014C040I2 (tr) |
BG (1) | BG64837B1 (tr) |
BR (1) | BR9914606A (tr) |
CA (1) | CA2346438C (tr) |
CY (1) | CY2014027I2 (tr) |
CZ (1) | CZ299409B6 (tr) |
DE (2) | DE19853487A1 (tr) |
DK (1) | DK1131065T3 (tr) |
EE (1) | EE04389B1 (tr) |
ES (1) | ES2195664T3 (tr) |
FR (1) | FR14C0051I2 (tr) |
HK (1) | HK1042242B (tr) |
HU (2) | HU226689B1 (tr) |
IL (2) | IL142728A0 (tr) |
LT (1) | LTC1131065I2 (tr) |
LU (1) | LU92488I2 (tr) |
ME (1) | ME00731B (tr) |
MX (1) | MXPA01005007A (tr) |
NO (3) | NO333257B1 (tr) |
NZ (1) | NZ510247A (tr) |
PL (2) | PL226074B1 (tr) |
PT (1) | PT1131065E (tr) |
RS (1) | RS49995B (tr) |
RU (1) | RU2215524C2 (tr) |
SI (1) | SI1131065T1 (tr) |
SK (1) | SK285601B6 (tr) |
TR (1) | TR200101204T2 (tr) |
WO (1) | WO2000030622A2 (tr) |
ZA (1) | ZA200202335B (tr) |
Families Citing this family (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
DE10000577A1 (de) * | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
US6912052B2 (en) * | 2000-11-17 | 2005-06-28 | Cymer, Inc. | Gas discharge MOPA laser spectral analysis module |
RU2290946C2 (ru) | 2001-01-12 | 2007-01-10 | Фумафарм Аг | Амиды фумаровой кислоты |
DE10101307A1 (de) * | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
US20050259709A1 (en) * | 2002-05-07 | 2005-11-24 | Cymer, Inc. | Systems and methods for implementing an interaction between a laser shaped as a line beam and a film deposited on a substrate |
DE10217314A1 (de) * | 2002-04-18 | 2003-11-13 | Fumapharm Ag Muri | Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere |
WO2004112773A1 (fr) * | 2003-04-24 | 2004-12-29 | Shin-Jen Shiao | Compositions pharmaceutiques utilisees pour le traitement de maladie immune et amelioration |
US7277188B2 (en) * | 2003-04-29 | 2007-10-02 | Cymer, Inc. | Systems and methods for implementing an interaction between a laser shaped as a line beam and a film deposited on a substrate |
SI1663197T1 (sl) | 2003-09-09 | 2008-06-30 | Biogen Idec Internat Gmbh | Uporaba derivatov fumarne kisline za zdravljenje sräśne insuficience in astme |
DE10360869A1 (de) * | 2003-09-09 | 2005-04-07 | Fumapharm Ag | Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma |
DE10342423A1 (de) * | 2003-09-13 | 2005-04-14 | Heidland, August, Prof. Dr.med. Dr.h.c. | Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden |
US6873418B1 (en) | 2003-09-30 | 2005-03-29 | Cymer, Inc. | Optical mountings for gas discharge MOPA laser spectral analysis module |
US6894785B2 (en) * | 2003-09-30 | 2005-05-17 | Cymer, Inc. | Gas discharge MOPA laser spectral analysis module |
CA2478458A1 (en) * | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
ES2387192T3 (es) | 2004-10-08 | 2012-09-17 | Forward Pharma A/S | Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico |
US20080004344A1 (en) * | 2004-11-10 | 2008-01-03 | Aditech Pharma Ab | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use |
US7653095B2 (en) * | 2005-06-30 | 2010-01-26 | Cymer, Inc. | Active bandwidth control for a laser |
DE602006011910D1 (de) * | 2005-07-07 | 2010-03-11 | Aditech Pharma Ag | Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung |
US20080227847A1 (en) * | 2005-07-07 | 2008-09-18 | Aditech Pharma Ab | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use |
EP1940382A2 (en) * | 2005-10-07 | 2008-07-09 | Aditech Pharma AB | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
WO2007042034A1 (en) * | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
US7679029B2 (en) * | 2005-10-28 | 2010-03-16 | Cymer, Inc. | Systems and methods to shape laser light as a line beam for interaction with a substrate having surface variations |
US7317179B2 (en) * | 2005-10-28 | 2008-01-08 | Cymer, Inc. | Systems and methods to shape laser light as a homogeneous line beam for interaction with a film deposited on a substrate |
EP2680010A1 (en) | 2007-02-08 | 2014-01-01 | Biogen Idec MA Inc. | Nrf2 screening assays and related methods and compositions |
EP3135282A1 (en) * | 2007-02-08 | 2017-03-01 | Biogen MA Inc. | Neuroprotection in demyelinating diseases |
DE102008030023A1 (de) | 2008-06-16 | 2009-12-17 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Arzneimittel zur Behandlung einer durch Parasiten verursachten Krankheit |
PL2334378T3 (pl) * | 2008-08-19 | 2014-09-30 | Xenoport Inc | Proleki wodorofumaranu metylu, ich kompozycje farmaceutyczne i sposoby zastosowania |
PL2379063T5 (pl) * | 2009-01-09 | 2022-07-04 | Fwp Ip Aps | Preparat farmaceutyczny obejmujący jeden lub więcej estrów kwasu fumarowego w matrycy erozjnej |
NZ595941A (en) | 2009-04-29 | 2014-02-28 | Biogen Idec Inc | Treatment of neurodegeneration and neuroinflammation |
DK2533634T3 (en) * | 2010-02-12 | 2016-01-25 | Biogen Ma Inc | NEURO PROTECTIVE demyelinating diseases |
US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
WO2011116091A1 (en) | 2010-03-17 | 2011-09-22 | Novartis Ag | Dispenser |
LT2558499T (lt) | 2010-04-16 | 2017-07-25 | Biogen Ma Inc. | Antikūnai prieš vla-4 |
AU2012258558A1 (en) * | 2011-05-26 | 2013-05-02 | Biogen Ma Inc. | Methods of treating multiple sclerosis and preserving and/or increasing myelin content |
KR20150080037A (ko) | 2011-06-08 | 2015-07-08 | 바이오젠 엠에이 인코포레이티드 | 고순도 및 결정질 다이메틸 푸마레이트의 제조 방법 |
WO2013076216A1 (en) | 2011-11-24 | 2013-05-30 | Synthon Bv | Controlled release particles comprising dimethyl fumarate |
US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
NZ627980A (en) * | 2012-02-07 | 2016-12-23 | Biogen Ma Inc | Pharmaceutical compositions containing dimethyl fumarate |
RU2014136394A (ru) | 2012-02-07 | 2016-03-27 | Ксенопорт, Инк. | Морфолиноалкилфумаратные соединения, фармацевтические композиции и способы применения |
SG11201407322QA (en) * | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of multiple sclerosis |
CA2882730C (en) | 2012-08-22 | 2019-12-31 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
JP2015527372A (ja) * | 2012-08-22 | 2015-09-17 | ゼノポート,インコーポレイティド | 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法 |
CN103483194B (zh) * | 2012-11-30 | 2016-03-09 | 杨寅柯 | 一种2-氟代富马酸酯(结构式i)及其制备方法及应用 |
US20140171504A1 (en) | 2012-12-14 | 2014-06-19 | Georgia Regents Research Institute, Inc. | Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters |
TW201436790A (zh) | 2012-12-21 | 2014-10-01 | Biogen Idec Inc | 經氘取代之反丁烯二酸酯衍生物類 |
KR101379427B1 (ko) * | 2013-02-13 | 2014-03-28 | 경북대학교병원 | 디메틸푸마레이트를 유효성분으로 포함하는 신섬유증의 예방 또는 치료용 조성물 |
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
NZ723459A (en) | 2013-03-14 | 2017-12-22 | Alkermes Pharma Ireland Ltd | Prodrugs of fumarates and their use in treating various diseases |
WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
KR20210139485A (ko) | 2013-08-26 | 2021-11-22 | 에프더블유피 아이피 에이피에스 | 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물 |
CN104415026A (zh) * | 2013-08-31 | 2015-03-18 | 成都渊源生物科技有限公司 | 氘代富马酸衍生物在治疗多发性硬化症中的应用 |
JP2016534133A (ja) | 2013-09-06 | 2016-11-04 | ゼノポート,インコーポレイティド | (n,n−ジエチルカルバモイル)メチル メチル(2e)ブト−2−エン−1,4−ジオエートの結晶形態、その合成方法及び使用 |
WO2015042294A1 (en) | 2013-09-18 | 2015-03-26 | Xenoport, Inc. | Nanoparticle compositions of dimethyl fumarate |
CN104434904B (zh) * | 2013-09-22 | 2018-09-04 | 深圳翰宇药业股份有限公司 | 一种复方微丸胶囊的制备方法及其制备的复方微丸胶囊 |
US20150094332A1 (en) * | 2013-09-27 | 2015-04-02 | Teva Pharmaceutical Industries, Ltd. | Laquinimod Combination Therapy For Treatment Of Multiple Sclerosis |
PT3079666T (pt) | 2013-12-12 | 2021-02-18 | Almirall Sa | Composições farmacêuticas que contêm fumarato de dimetilo |
US10172794B2 (en) | 2013-12-13 | 2019-01-08 | Biogen Ma Inc. | Controlled release dosage form for once daily administration of dimethyl fumarate |
CA2940845C (en) | 2014-02-24 | 2019-09-24 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
AU2015222880B2 (en) | 2014-02-28 | 2016-11-24 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
EP3650042A1 (en) | 2014-03-14 | 2020-05-13 | Biogen MA Inc. | Dimethyl fumarate and vaccination regimens |
US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
CN104027311A (zh) * | 2014-05-09 | 2014-09-10 | 万特制药(海南)有限公司 | 一种含有富马酸二甲酯的肠溶缓释微丸 |
WO2016061393A1 (en) | 2014-10-15 | 2016-04-21 | Xenoport, Inc. | Fumarate compounds, pharmaceutical compositions, and methods of use |
DE102014015314A1 (de) * | 2014-10-17 | 2016-04-21 | Ppm-Medical Holding Gmbh | Mittel zur unterstützenden Immunmodulation |
MA40985A (fr) | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
CN104490849A (zh) * | 2014-11-24 | 2015-04-08 | 广东东阳光药业有限公司 | 一种高密度的富马酸二甲酯肠溶颗粒及其制备方法 |
WO2016089648A1 (en) | 2014-12-01 | 2016-06-09 | Vtv Therapeutics Llc | Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof |
CA2969847A1 (en) | 2014-12-10 | 2016-06-16 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
KR102283582B1 (ko) | 2014-12-23 | 2021-07-30 | 한미약품 주식회사 | 푸마르산 에스테르를 함유하는 미니-정제 형태의 약제학적 제제 |
CN107847451A (zh) * | 2015-02-02 | 2018-03-27 | 英仕柏集团有限责任公司 | 稳定的富马酸二烷基酯组合物 |
CA2972179C (en) * | 2015-02-08 | 2021-10-26 | Alkermes Pharma Ireland Limited | Monomethylfumarate prodrug compositions |
WO2016147108A1 (en) * | 2015-03-17 | 2016-09-22 | Hetero Research Foundation | Pharmaceutical compositions of dimethyl fumarate |
WO2016160635A1 (en) | 2015-03-27 | 2016-10-06 | Sytheon Limited | Compositions and methods for treating psoriasis |
CA2987895A1 (en) | 2015-06-01 | 2016-12-08 | Sun Pharmaceutical Industries Ltd. | Pharmaceutical compositions of dimethyl fumarate |
CN107920997A (zh) | 2015-06-17 | 2018-04-17 | 比奥根Ma公司 | 富马酸二甲酯颗粒和其药物组合物 |
US10213411B2 (en) | 2015-08-27 | 2019-02-26 | Vijaykumar Rajasekhar | Use of prodrugs of fumarates in treating heart failure diseases |
WO2017056107A1 (en) | 2015-09-28 | 2017-04-06 | Natco Pharma Ltd | Pharmaceutical compositions of dimethyl fumarate |
WO2017060400A1 (en) | 2015-10-07 | 2017-04-13 | Neurovive Pharmaceutical Ab | Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions |
DE102016103242A1 (de) | 2016-02-24 | 2017-08-24 | Flexopharm Brain Gmbh & Co. Kg | Mittel zur unterstützenden Immunmodulation |
CA3003237A1 (en) * | 2015-10-28 | 2017-05-04 | Sun Pharmaceutical Industries Limited | Pharmaceutical compositions of dimethyl fumarate |
US10463642B2 (en) | 2016-02-01 | 2019-11-05 | Vijaykumar Rajasekhar | Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate |
WO2017145036A1 (en) * | 2016-02-25 | 2017-08-31 | Aurobindo Pharma Ltd | Pharmaceutical compositions comprising dimethyl fumarate |
CN106265621B (zh) * | 2016-09-19 | 2019-05-17 | 苏州大学 | 富马酸二甲酯在制备预防和治疗移植物抗宿主病及移植物抗白血病药物中的应用 |
GR1009149B (el) | 2016-10-25 | 2017-10-31 | Φαρματεν Αβεε | Φαρμακευτικα σκευασματα που περιλαμβανουν εναν εστερα φουμαρικου οξεως και μεθοδος παραγωγης αυτων |
TR201616998A1 (tr) * | 2016-11-23 | 2018-06-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Di̇meti̇l fumarat i̇çeren geci̇kti̇ri̇lmi̇ş salim sağlayan dozaj formlari |
DE102017105036A1 (de) | 2017-03-09 | 2018-09-13 | Flexopharm Brain Gmbh & Co. Kg | Mittel zur Anwendung bei der Behandlung der Dyslipidämie |
WO2018234584A1 (en) | 2017-06-23 | 2018-12-27 | Almirall, S.A. | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE |
JP7224067B2 (ja) | 2019-05-31 | 2023-02-17 | キュラクル カンパニー リミテッド | フマル酸ジメチルを含有する腸溶性錠剤 |
RU2742745C1 (ru) * | 2019-09-24 | 2021-02-10 | Акционерное общество "Исследовательский Институт Химического Разнообразия" | Лекарственная форма в виде капсулы, содержащая таблетки с диметилфурмаратом |
US11903918B2 (en) | 2020-01-10 | 2024-02-20 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
TW202146015A (zh) | 2020-03-06 | 2021-12-16 | 瑞士商艾克泰聯製藥有限公司 | 減緩腦體積損失之方法 |
CN111418675A (zh) * | 2020-04-23 | 2020-07-17 | 王坤全 | 一种幼儿保健茶 |
WO2021144478A2 (en) | 2020-05-06 | 2021-07-22 | Imcyse Sa | Combination treatment for fumarate-related diseases |
WO2022203432A1 (ko) | 2021-03-25 | 2022-09-29 | 주식회사 큐라클 | 특정 약동학적 매개변수를 나타내는 디메틸푸마레이트를 유효성분으로 함유한 약학적 조성물 |
US11951097B2 (en) | 2021-10-11 | 2024-04-09 | Vanda Pharmaceuticals Inc. | Methods of treating multiple sclerosis |
WO2023152290A1 (en) | 2022-02-11 | 2023-08-17 | Actelion Pharmaceuticals Ltd | Methods of slowing an increase in brain ventricular volume |
CN115590831A (zh) * | 2022-10-26 | 2023-01-13 | 力品药业(厦门)股份有限公司(Cn) | 一种富马酸二甲酯缓释微片及其制备方法 |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1972109U (de) | 1965-10-20 | 1967-11-09 | Qualitrol Corp | Schnellventil zum schutz elektrischer geraete. |
DE1618162B1 (de) | 1967-05-20 | 1971-05-19 | Basf Ag | Verfahren zur Herstellung con Cyclohexan-1.2.3.4.5.6-hexan-carbonsäure |
US3832287A (en) | 1972-03-02 | 1974-08-27 | Lilly Co Eli | Dipeptide antibiotic and method for the production thereof |
DE2212369A1 (de) | 1972-03-15 | 1973-09-20 | Basf Ag | Cyclohexanhexacarbonsaeure |
DE2530372A1 (de) * | 1975-07-08 | 1977-01-13 | Walter Dr Schweckendiek | Pharmazeutische zubereitungen zur behandlung von psoriasis |
DE2621214C3 (de) * | 1976-05-13 | 1981-11-12 | Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen | Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen |
DE2840498C2 (de) * | 1978-09-18 | 1980-04-10 | Walter Dr. 6700 Ludwigshafen Schweckendiek | Pharmazeutische Zubereitungen zur Behandlung von Psoriasis |
DE3127432A1 (de) | 1981-07-11 | 1983-02-03 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von fumarsaeuremonoester |
US4894366A (en) | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
CH664150A5 (de) * | 1985-01-15 | 1988-02-15 | Peter Paul Prof Dr Speiser | Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen. |
US5149695A (en) * | 1985-01-15 | 1992-09-22 | Speiser Peter P | Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same |
JPS61194020A (ja) | 1985-02-22 | 1986-08-28 | Dai Ichi Seiyaku Co Ltd | 網膜症治療剤 |
GB2176999B (en) | 1985-06-22 | 1989-07-12 | Stanley Stewart Davis | Sustained release medicament |
DE3531597A1 (de) | 1985-09-04 | 1987-03-05 | Bioferon Biochem Substanz | Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur behandlung psoriatischer erkrankungen |
IL83775A (en) | 1987-09-04 | 1991-12-15 | Dexter Chemical Corp | Amino acid esters and amides of fumaric acid and pharmaceutical compositions containing them for use in the treatment of psoriasis |
US5214196A (en) | 1987-09-04 | 1993-05-25 | Dexter Chemical Corporation | Diethyl ester of di-glycyl fumaramide |
US5242905A (en) * | 1987-09-04 | 1993-09-07 | Dexter Chemical Corporation | Pharmaceutical compositions for the treatment of psoriasis |
US5424332A (en) | 1987-10-19 | 1995-06-13 | Speiser; Peter P. | Pharmaceutical composition and process for the production thereof |
US4959389A (en) * | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
DE3834794A1 (de) | 1988-10-12 | 1990-04-19 | F Schielein | Oral zu verabreichendes mittel zur behandlung von psoriasis |
AU1271592A (en) | 1991-01-18 | 1992-08-27 | Dexter Chemical Corporation | Malic acid derivatives and compositions for the treatment of psoriasis |
IT1251166B (it) | 1991-08-09 | 1995-05-04 | Chiesi Farma Spa | Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono |
DE4494231T1 (de) | 1993-06-08 | 1996-10-17 | Raymond K Brown | Therapeutische Zusammensetzung und ihre Anwendung |
CA2125763C (en) | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | P40 homodimer of interleukin-12 |
US7888458B1 (en) | 1993-11-30 | 2011-02-15 | John B. Harley | Diagnostics and therapy of epstein-barr virus in autoimmune disorders |
US5407772A (en) | 1993-11-30 | 1995-04-18 | Xerox Corporation | Unsaturated polyesters |
JPH09510222A (ja) | 1994-03-16 | 1997-10-14 | ノボ ノルディスク アクティーゼルスカブ | 2,3,4,5−テトラヒドロ−1h−3−ベンゾアゼピン化合物の酸付加塩 |
US6576236B1 (en) | 1994-07-01 | 2003-06-10 | Dana Farber Cancer Institute | Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain |
GB2291422A (en) | 1994-07-18 | 1996-01-24 | Fujisawa Pharmaceutical Co | 4-phenyl-pyrido[2,3-b]pyrazin-4-ones |
IL110380A0 (en) | 1994-07-20 | 1994-10-21 | Agis Ind 1983 Ltd | Antiviral topical pharmaceutical compositions |
US5589504A (en) | 1994-07-26 | 1996-12-31 | Cornell Research Foundation, Inc. | Treatment of newborn jaundice |
CN1125141A (zh) | 1994-12-22 | 1996-06-26 | 杭州中美华东制药有限公司 | 一种含环孢菌素a的固体分散物及其外用剂型上的用途 |
US6011000A (en) | 1995-03-03 | 2000-01-04 | Perrine; Susan P. | Compositions for the treatment of blood disorders |
CA2226915A1 (en) | 1995-09-13 | 1997-03-20 | Yoshikazu Ohta | Immunosuppressant |
JPH1067658A (ja) * | 1995-09-13 | 1998-03-10 | Takeda Chem Ind Ltd | 免疫抑制剤 |
JP4004567B2 (ja) | 1996-02-14 | 2007-11-07 | アステラス製薬株式会社 | Wb2663b物質を含有する免疫抑制剤 |
KR970064620A (ko) * | 1996-03-05 | 1997-10-13 | 임성기 | 사이클로스포린-함유 외용약제 조성물 |
DE69704057T2 (de) | 1996-04-22 | 2001-09-13 | Shionogi & Co | Terphenylverbindungen und sie enthaltende arzneimittel |
DE69703040T2 (de) | 1996-05-22 | 2001-05-03 | Univ Alberta Edmonton | Typ-2 chemokine-bindende proteine und verfahren zu deren verwendung |
US6046180A (en) | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
WO1998004290A2 (en) | 1996-07-26 | 1998-02-05 | Perrine Susan P | Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders |
DE19651551C2 (de) * | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioidantagonisthaltige galenische Formulierung |
AU5474198A (en) | 1996-12-24 | 1998-07-17 | National Research Council Of Canada | Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals |
US5972363A (en) | 1997-04-11 | 1999-10-26 | Rohm And Haas Company | Use of an encapsulated bioactive composition |
DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
CA2306875C (en) | 1997-10-24 | 2011-01-04 | John P. Blass | Nutritional supplement for cerebral metabolic insufficiencies |
DE19814358C2 (de) * | 1998-03-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn |
DE19839566C2 (de) * | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
DE19848260C2 (de) | 1998-10-20 | 2002-01-17 | Fumapharm Ag Muri | Fumarsäure-Mikrotabletten |
DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
DE10000577A1 (de) | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
EP1272614B1 (en) | 2000-02-11 | 2007-08-15 | Philadelphia Health and Education Corporation | Differentiation of bone marrow cells into neuronal cells and uses therefor |
US6812248B2 (en) | 2000-07-05 | 2004-11-02 | John Hopkins University School Of Medicine | Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes |
DE10101307A1 (de) | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
RU2290946C2 (ru) | 2001-01-12 | 2007-01-10 | Фумафарм Аг | Амиды фумаровой кислоты |
CA2463624A1 (en) | 2001-10-15 | 2003-04-24 | National Research Council Of Canada | Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications |
DE10217314A1 (de) | 2002-04-18 | 2003-11-13 | Fumapharm Ag Muri | Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere |
DE50304744D1 (de) | 2003-04-28 | 2006-10-05 | Biofrontera Bioscience Gmbh | Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis |
SI1663197T1 (sl) | 2003-09-09 | 2008-06-30 | Biogen Idec Internat Gmbh | Uporaba derivatov fumarne kisline za zdravljenje sräśne insuficience in astme |
DE10342423A1 (de) | 2003-09-13 | 2005-04-14 | Heidland, August, Prof. Dr.med. Dr.h.c. | Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden |
US20050096369A1 (en) | 2003-11-04 | 2005-05-05 | Hoang Ba X. | Compositions and methods for treating cellular proliferation disorders |
MX2007000142A (es) | 2004-06-30 | 2007-03-26 | Combinatorx Inc | Metodos y reactivos para el tratamiento de desordenes metabolicos. |
ES2387192T3 (es) | 2004-10-08 | 2012-09-17 | Forward Pharma A/S | Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico |
WO2006050730A1 (en) | 2004-11-10 | 2006-05-18 | Aditech Pharma Ab | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
CA2587597A1 (en) | 2004-11-19 | 2006-05-26 | Biogen Idec Ma Inc. | Treatment for multiple sclerosis |
DE102005022845A1 (de) | 2005-05-18 | 2006-11-23 | Fumapharm Ag | Thiobernsteinsäurederivate und deren Verwendung |
EP2680010A1 (en) | 2007-02-08 | 2014-01-01 | Biogen Idec MA Inc. | Nrf2 screening assays and related methods and compositions |
EP3135282A1 (en) | 2007-02-08 | 2017-03-01 | Biogen MA Inc. | Neuroprotection in demyelinating diseases |
NZ595941A (en) | 2009-04-29 | 2014-02-28 | Biogen Idec Inc | Treatment of neurodegeneration and neuroinflammation |
-
1998
- 1998-11-19 DE DE19853487A patent/DE19853487A1/de not_active Withdrawn
-
1999
- 1999-10-29 WO PCT/EP1999/008215 patent/WO2000030622A2/de active IP Right Grant
- 1999-10-29 IL IL14272899A patent/IL142728A0/xx active IP Right Grant
- 1999-10-29 JP JP2000583505A patent/JP2002530324A/ja not_active Withdrawn
- 1999-10-29 RS YUP-299/01A patent/RS49995B/sr unknown
- 1999-10-29 CN CNA200410011769XA patent/CN1615839A/zh active Pending
- 1999-10-29 CA CA002346438A patent/CA2346438C/en not_active Expired - Lifetime
- 1999-10-29 ME MEP-2001-299A patent/ME00731B/me unknown
- 1999-10-29 TR TR2001/01204T patent/TR200101204T2/tr unknown
- 1999-10-29 PL PL385418A patent/PL226074B1/pl unknown
- 1999-10-29 CZ CZ20010939A patent/CZ299409B6/cs not_active IP Right Cessation
- 1999-10-29 US US09/831,620 patent/US6509376B1/en not_active Expired - Lifetime
- 1999-10-29 MX MXPA01005007A patent/MXPA01005007A/es unknown
- 1999-10-29 DK DK99972532T patent/DK1131065T3/da active
- 1999-10-29 BR BR9914606-1A patent/BR9914606A/pt not_active Application Discontinuation
- 1999-10-29 RU RU2001116566/14A patent/RU2215524C2/ru active
- 1999-10-29 SI SI9930309T patent/SI1131065T1/xx unknown
- 1999-10-29 HU HU0103182A patent/HU226689B1/hu active Protection Beyond IP Right Term
- 1999-10-29 EP EP99972532A patent/EP1131065B1/de not_active Expired - Lifetime
- 1999-10-29 SK SK576-2001A patent/SK285601B6/sk not_active IP Right Cessation
- 1999-10-29 PL PL348147A patent/PL205948B1/pl unknown
- 1999-10-29 CN CNB998123889A patent/CN1182844C/zh not_active Expired - Lifetime
- 1999-10-29 ES ES99972532T patent/ES2195664T3/es not_active Expired - Lifetime
- 1999-10-29 DE DE59905954T patent/DE59905954D1/de not_active Expired - Lifetime
- 1999-10-29 NZ NZ510247A patent/NZ510247A/en not_active IP Right Cessation
- 1999-10-29 AT AT99972532T patent/ATE242633T1/de active
- 1999-10-29 PT PT99972532T patent/PT1131065E/pt unknown
- 1999-10-29 EE EEP200100266A patent/EE04389B1/xx active Protection Beyond IP Right Term
-
2001
- 2001-03-12 NO NO20011242A patent/NO333257B1/no not_active IP Right Cessation
- 2001-03-30 BG BG105396A patent/BG64837B1/bg unknown
- 2001-04-22 IL IL142728A patent/IL142728A/en active Protection Beyond IP Right Term
-
2002
- 2002-03-22 ZA ZA200202335A patent/ZA200202335B/en unknown
- 2002-05-28 HK HK02103958.2A patent/HK1042242B/zh not_active IP Right Cessation
- 2002-07-17 US US10/197,077 patent/US7320999B2/en not_active Expired - Lifetime
-
2004
- 2004-12-21 JP JP2004368948A patent/JP2005097323A/ja active Pending
-
2007
- 2007-06-20 US US11/765,563 patent/US7612110B2/en not_active Expired - Fee Related
- 2007-06-20 US US11/765,578 patent/US7619001B2/en not_active Expired - Fee Related
-
2009
- 2009-03-17 US US12/405,661 patent/US7803840B2/en not_active Expired - Fee Related
- 2009-03-17 US US12/405,665 patent/US7915310B2/en not_active Expired - Lifetime
- 2009-08-10 JP JP2009185402A patent/JP5828614B2/ja not_active Expired - Lifetime
-
2011
- 2011-03-04 US US13/040,914 patent/US8759393B2/en not_active Expired - Fee Related
-
2012
- 2012-08-24 JP JP2012185136A patent/JP2012255020A/ja not_active Withdrawn
- 2012-09-12 US US13/612,221 patent/US8524773B2/en not_active Expired - Fee Related
- 2012-12-07 NO NO20121479A patent/NO20121479L/no not_active Application Discontinuation
-
2013
- 2013-03-13 US US13/800,128 patent/US20140066505A1/en not_active Abandoned
-
2014
- 2014-06-25 FR FR14C0051C patent/FR14C0051I2/fr active Active
- 2014-06-26 BE BE2014C040C patent/BE2014C040I2/fr unknown
- 2014-06-26 NO NO2014016C patent/NO2014016I2/no unknown
- 2014-06-27 LU LU92488C patent/LU92488I2/xx unknown
- 2014-06-30 LT LTPA2014023C patent/LTC1131065I2/lt unknown
- 2014-07-01 HU HUS1400034C patent/HUS1400034I1/hu unknown
- 2014-07-16 CY CY2014027C patent/CY2014027I2/el unknown
-
2015
- 2015-10-22 JP JP2015207653A patent/JP2016047830A/ja not_active Withdrawn
-
2017
- 2017-08-03 JP JP2017150481A patent/JP2017226681A/ja not_active Withdrawn
-
2019
- 2019-03-29 JP JP2019066965A patent/JP2019123738A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR200101204T2 (tr) | Dialkil Fumaratlarının kullanımı | |
HUP0300814A2 (hu) | Peptidszelekciós módszer | |
TR200500745T2 (tr) | Damar gelişimi inhibitörleri olarak kuinazolin türevleri. | |
MXPA02007932A (es) | Analogos de nucleosidos con base biciclica modificada con carboxamidina. | |
BR9406893A (pt) | Emprego de nona- e decapeptideos para a preparação de um medicamento para o combate da aids | |
HUP0100539A2 (hu) | D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására | |
NO990934D0 (no) | Anvendelse av arakidonsyre og/eller dokosaheksansyre for fremstilling av et medikament for behandling av dyspraksi | |
ATE234082T1 (de) | Adenosin enthaltendes arzneimittel | |
HK1088926A1 (en) | Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical proparations | |
NO20034417L (no) | Engangs vaginalkanyle for samtidig administrasjon av medikamenter i ulike former | |
MX9803610A (es) | Utilizacion de flupirtina para la profilaxis y la terapia de enfermedades que van a compañadas de un deterioro del sistema celular hermatopoyetico. | |
PT1144420E (pt) | Fosfatidilinositois sulfatados a sua preparacao e a sua utilizacao | |
DE60008293D1 (de) | Pharmazeutische zusammensetzung die einen no donor enthält und dessen therapeutische anwendung | |
HUP0100937A2 (hu) | Többszörösen elágazó peptidkonstrukciókat tartalmazó liposzómák és alkalmazásuk humán immundeficiencia vírus ellen | |
DE60322871D1 (de) | Thaltende zubereitungen | |
ATE230998T1 (de) | Arzneimittel zur manipulation der t-zell immunantwort | |
Firshein | FDA persists in trying out drugs on combat troops. | |
Lammi et al. | Should Congress curb the FDA's power over drugs, vitamins, and medical devices? |